Clinical Trial Update: Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the combination of sorafenib and fulvestrant in locally advanced or metastatic breast cancer that progressed on aromatase inhibi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• Nexavar (Sorafenib)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2011-09-05